2023 ONA Summit Archives

Not only may co-testing help detect more cases of invasive cervical cancer, but it also may lower ov

ONA Summit 2023

Characteristics, Treatment Options for Patients With Advanced Gynecologic Cancers

By

Joyce Pagan

March 19, 2023

A presentation at the 2023 ONA Summit reviewed diagnosis and treatment recommendations for uterine, ovarian, and endometrial cancers.

Bone marrow biopsy from myelodysplastic condition under the microscope view. Histology tissue of bone marrow biopsy.

ONA Summit 2023

Update on Therapeutic Options for Myelofibrosis

By

Sara M. Tinsley-Vance, PhD, APRN, AOCN

March 19, 2023

A review of myelofibrosis, including an update on treatment options, was presented at the 2023 ONA Summit.

In Patients With Renal Cell Carcinoma Receiving Everolimus, Acute Kidney Injury is Common

ONA Summit 2023

New Treatments, New Challenges in the Treatment of Bladder and Renal Cancers

By

Mary W. Dunn, MSN, RN, OCN, NP-C

March 18, 2023

A discussion of new treatment options that have improved prognosis for patients with bladder cancer and renal cell carcinoma is the focus of a presentation at the 2023 ONA Summit.

Vandetanib May Not Be Effective for Advanced Biliary Tract Cancer

ONA Summit 2023

Advanced Gastric and Colorectal Cancer Diagnosis and Treatment

By

Nina N. Grenon, DNP-AOCN

March 18, 2023

Management strategies aimed at improving outcomes in patients with CRC and gastric cancer were presented at the 2023 ONA Summit.

ONA Summit 2023

Treatment Selection and Symptom Management After MDS/MDN Diagnosis

By

Sandra E. Kurtin, PhD, ANP-BC, AOCN

March 18, 2023

A review of MDS/MDN, including new WHO guidelines and collaborative strategies for managing the care of patients with lower-risk MDS.

Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.

ONA Summit 2023

Pivotal Studies Lead to New Treatment Landscape for Metastatic HER2-Positive Breast Cancer

By

Noele Myers, CRNP, MSN, FNP-BC, AOCNP

March 17, 2023

A review of patient assessment, treatment options, and management strategies for adverse effects in patients with metastatic HER2-positive breast cancer were presented at the 2023 ONA Summit.

This frontal view x-ray of the chest shows advanced stage non-small cell lung cancer (NSCLC) of a 50-year-old woman with a long history of smoking and emphysema. The orange area depicts collapsed lung tissue at the base of the right lung, and the yellow area highlights a pleura-based density along the right hemithorax.

ONA Summit 2023

Updates in Targeted Therapies, Management Strategies for Non-Small Cell Lung Cancer

By

Marianne Davies, DNP, ACNP, AOCNP

March 17, 2023

In an oral presentation at the 2023 ONA Summit, a thoracic oncology nurse practitioner reviewed the advances in the treatment of NSCLC and management of related adverse effects.

ONA Summit 2023

Achieving, Managing Patient Care During Maintenance Therapy for AML

By

Joyce Pagan

March 17, 2023

The unique needs of patients with AML undergoing maintenance therapy, including care disparities and challenges, are discussed at the 2023 ONA Summit.

ONA Summit 2023

ONA Summit Highlights Collaboration, How Oncology Nurses Thrive Under Pressure

March 15, 2023

Here is a preview of this year’s ONA Summit with a link to the registration page.

Diagnosis & Disease Information